Allergan Chief Executive Officer David Pyott said in an interview with the Wall Street Journal he's looking at potential sizable acquisitions as he seeks to fend off a $53 billion hostile takeover offer from Valeant Pharmaceuticals and activist investor Bill Ackman. He said Allergan is considering both U.S. companies and companies located overseas, which could lead to a tax-cutting deal. Pyott said in the interview that Allergan's earnings results out later this month would reinforce his stance that the future value of the Botox-maker will exceed Valeant's offer price.

If you liked this article you might like

Jim Cramer: Drug Stocks on the Move

Jim Cramer: Drug Stocks on the Move

Allergan Exec on Medical Aesthetics: 'The Future Is About Market Expansion'

Allergan Exec on Medical Aesthetics: 'The Future Is About Market Expansion'

Cramer: 10 Stock Surprises

Cramer: 10 Stock Surprises

Purdue Pharma to Downplay Opioids, Dump 50% of Sales Staff

Purdue Pharma to Downplay Opioids, Dump 50% of Sales Staff

Generic Drug Makers Hurt By Latest Federal Government Budget

Generic Drug Makers Hurt By Latest Federal Government Budget